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 Hypermethylation of CpG islands in the promoter region of genes 
is associated with gene silencing, may serve as a mechanism to inac-
tivate tumor suppressor genes in colorectal cancer carcinogenesis, 
and can be analyzed easily by using methylation-specific poly-
merase chain reaction (PCR). Identification of methylation markers 
that are sensitive and specific for colorectal cancer detection may 
improve the early detection of this disease. Previous microarray 
experiments ( 1 ) to identify genes that are epigenetically regulated 
 Affiliations of authors: Department of Pathology (VM, MHFML, SMvdB, 
DMEIH, JPJdH, KADW, KLJD, IEJMP-H, FS, APdB, MvE) and Department of 
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 N-Myc Downstream-Regulated Gene 4 ( NDRG4 ): A 
Candidate Tumor Suppressor Gene and Potential 
Biomarker for Colorectal Cancer 
 Veerle  Melotte ,  Marjolein H. F. M.  Lentjes ,  Sandra M.  van den Bosch ,  Debby M. E. I.  Hellebrekers , 
 Joep P. J.  de Hoon ,  Kim A. D.  Wouters ,  Kathleen L. J.  Daenen ,  Iris E. J. M.  Partouns-Hendriks , 
 Filip  Stessels ,  Joost  Louwagie ,  Kim M.  Smits ,  Matty P.  Weijenberg ,  Silvia  Sanduleanu ,  
 Carolina A. J.  Khalid-de Bakker ,  Frank A.  Oort ,  Gerrit A.  Meijer ,  Daisy M. A. E.  Jonkers ,  
 James G.  Herman ,  Adriaan P.  de Bruïne ,  Manon  van Engeland 
  Background  Identification of hypermethylated tumor suppressor genes in body fluids is an appealing strategy for the 
noninvasive detection of colorectal cancer. Here we examined the role of N-Myc downstream-regulated 
gene 4 ( NDRG4 ) as a novel tumor suppressor and biomarker in colorectal cancer. 
  Methods  NDRG4 promoter methylation was analyzed in human colorectal cancer cell lines, colorectal tissue, and 
noncancerous colon mucosa by using methylation-specific polymerase chain reaction (PCR) and bisulfite 
sequencing. NDRG4 mRNA and protein expression were studied using real-time – PCR and immunohis-
tochemistry, respectively. Tumor suppressor functions of NDRG4 were examined by colony formation, cell 
proliferation, and migration and invasion assays in colorectal cancer cell lines that were stably transfected 
with an NDRG4 expression construct. Quantitative methylation-specific PCR was used to examine the util-
ity of  NDRG4 promoter methylation as a biomarker in fecal DNA from 75 colorectal cancer patients and 75 
control subjects. All  P values are two-sided. 
  Results  The prevalence of  NDRG4 promoter methylation in two independent series of colorectal cancers was 86% 
(71/83) and 70% (128/184) compared with 4% (2/48) in noncancerous colon mucosa ( P < .001). NDRG4 
mRNA and protein expression were decreased in colorectal cancer tissue compared with noncancerous 
colon mucosa. NDRG4 overexpression in colorectal cancer cell lines suppressed colony formation 
( P = .014), cell proliferation ( P < .001), and invasion ( P < .001).  NDRG4 promoter methylation analysis in 
fecal DNA from a training set of colorectal cancer patients and control subjects yielded a sensitivity of 61% 
(95% confidence interval [CI] = 43% to 79%) and a specificity of 93% (95% CI = 90% to 97%). An indepen-
dent test set of colorectal cancer patients and control subjects yielded a sensitivity of 53% (95% 
CI = 39% to 67%) and a specificity of 100% (95% CI = 86% to 100%). 
  Conclusions  NDRG4 is a candidate tumor suppressor gene in colorectal cancer whose expression is frequently inacti-
vated by promoter methylation.  NDRG4 promoter methylation is a potential biomarker for the noninvasive 
detection of colorectal cancer in stool samples. 
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in tumor endothelium revealed 81 genes whose expression was 
decreased in tumor endothelial cells compared with quiescent 
endothelial cells and that were reexpressed after treatment with the 
DNA methylation inhibitor 5-aza-2 ′ -deoxycytidine (DAC) and the 
histone deacetylase inhibitor trichostatin A. Silencing of these 
genes in tumor endothelium was associated with modifications of 
histones in the promoter regions but not with promoter CpG island 
methylation ( 1 ). It is interesting that 21 (26%) of the 81 genes were 
reported to be hypermethylated at their promoters and silenced in 
various tumor types, suggesting that expression of those genes in 
tumor cells may be regulated by promoter methylation ( 1 ). 
 One of the identifi ed genes was N-Myc downstream-regulated 
gene 4 ( NDRG4 ; also known as  SMAP-8 and  BDM1 ). The protein 
encoded by this gene, NDRG4, is a member of the NDRG protein 
family, which comprises four members named NDRG1 – 4 that 
have 57% – 65% amino acid sequence homology ( 2 , 3 ). NDRG1 is 
the most extensively studied member of the NDRG family. 
Expression of NDRG1 is decreased in cancer cells ( 4 – 9 ) but 
increases in cancer cells that are treated with DAC ( 5 , 6 ). It has 
been demonstrated that NDRG1 overexpression in colorectal 
cancer cell lines reduces their ability to metastasize in nude mice, 
and the NDRG1-mediated suppression of metastasis is thought to 
involve the induction of colorectal cancer cell differentiation and a 
partial reversal of the metastatic phenotype ( 6 ).  NDRG2 has been 
described as a candidate tumor suppressor gene ( 10 , 11 ) and dis-
plays promoter CpG island methylation in meningiomas ( 10 ) and 
in breast, liver, and lung cancer cell lines ( 12 ). To our knowledge, 
the roles of NDRG3 and NDRG4 in cancer have not been 
addressed. 
 The  NDRG4 gene is located at chromosome 16q21 – q22.3, 
spans 26 kilobases, and contains 17 exons that include the entire 
sequence of the three complementary DNA (cDNA) isoforms: 
 NDRG4-B ,  NDRG4-B var , and  NDRG4-H ( 2 ). To our knowledge, 
NDRG4 expression has only been described in the brain and heart 
using northern blot analysis. The molecular characterization of 
NDRG4 and the role of this protein in the nervous system have 
been investigated mainly in the rat ( 13 – 16 ), where it is thought to 
participate in processes that lead to cellular differentiation and 
neurite formation ( 14 ). 
 Here we examined the expression of  NDRG4 at the mRNA and 
protein levels in normal human colon mucosa and human colorec-
tal cancer tissue. In addition, we examined the mechanism under-
lying the decreased expression of  NDRG4 in colorectal cancer and 
investigated a possible tumor suppressor function of NDRG4 by 
measuring colony formation and cell proliferation, migration, and 
invasion in colorectal cancer cell lines that stably overexpressed 
 NDRG4 . Finally, we investigated the potential utility of  NDRG4 
promoter methylation as a biomarker for early detection of col-
orectal cancer in stool. 
 Materials and Methods 
 Study Population and Tissue Samples 
 NDRG4 promoter methylation was investigated in two indepen-
dent well-characterized tissue series from colorectal carcinoma 
patients, adenoma patients, and control subjects without cancer. 
The first hospital-based series consisted of formalin-fixed, paraffin-
embedded colorectal cancer tissues (n = 90) from patients who were 
older than 50 years at colorectal cancer diagnosis during 1995 – 2003 
and were retrospectively retrieved from the tissue archive of the 
Department of Pathology of the Maastricht University Medical 
Center. We also retrieved noncancerous healthy colon mucosa (n = 79) 
and adenoma (n = 62) tissues from these patients when available. 
As control tissue, we used histologically normal biopsy material 
from control subjects who underwent endoscopy during 1987 – 2004 
for nonspecific abdominal complaints (n = 51), adenoma biopsy 
samples from patients diagnosed during 1988 – 1995 and who did 
not develop colorectal cancer within 10 years of the adenoma diag-
nosis (n = 22), and resected colon mucosa from patients diagnosed 
during 1985 – 2004 with various inflammatory bowel conditions 
(n = 33). The inflammatory bowel conditions in the latter group of 
control tissues included Crohn disease (n = 1), colitis ulcerosa (n = 5), 
nonspecific inflammation (n = 9), and diverticulitis (n = 18). Control 
tissues were excluded if the patient had been diagnosed with col-
orectal cancer in the past or during follow-up. We excluded patients 
with and without colorectal cancer who had been diagnosed with 
additional cancers (excluding nonmelanoma skin cancer). 
Characteristics of the study populations are shown in Supplementary 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Identification of tumor suppressor gene promoter hypermethyla-
tion in fecal DNA is a promising strategy for noninvasive detection 
of colorectal cancer. N-Myc downstream-regulated gene 4 ( NDRG4 ) 
is a potential tumor suppressor in colorectal cancer. 
 Study design 
 NDRG4 promoter methylation and expression were analyzed in 
human colorectal cancer cell lines, noncancerous colon mucosa, 
and colorectal cancer tissue. NDRG4 tumor suppressor functions 
were examined in colorectal cancer cells.  NDRG4 promoter methy-
lation was examined as a potential biomarker in stool from colorec-
tal cancer patients and subjects without colorectal cancer. 
 Contribution 
 NDRG4 promoter methylation was prevalent in colorectal cancers 
compared with noncancerous colon mucosa. NDRG4 mRNA and 
protein expression were decreased in colorectal cancer tissue com-
pared with noncancerous colon mucosa.  NDRG4 overexpression in 
human colorectal cancer cells inhibited colony formation and cell 
proliferation and invasion in vitro. A methylation-specific poly-
merase chain reaction assay for  NDRG4 promoter methylation 
identified colorectal cancer when it was present (sensitivity) in 53% 
of colorectal cancer cases and correctly categorized a subject as 
cancer free (specificity) 100% of the time. 
 Implications 
 NDRG4 is a candidate tumor suppressor gene in colorectal cancer. 
 NDRG4 promoter methylation is a potential biomarker for the non-
invasive detection of colorectal cancer in stool samples. 
 Limitations 
 Not all stool samples from colorectal cancer patients were col-
lected before colonoscopy as was done for the control subjects. 
The colorectal cancer patients were older than the subjects without 
colorectal cancer. 
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Figure 1, Supplementary Table 1, and Supplementary Table 2 
(available online). Numbers of samples in the results section may 
differ from those indicated in the table because not all samples 
 could be amplified by using methylation-specific PCR. 
 The second population-based series of formalin-fi xed, paraffi n-
embedded colorectal cancers (n = 184) was randomly selected from 
the prospective Netherlands Cohort Study on Diet and Cancer 
(NLCS), which has been described in detail elsewhere ( 17 , 18 ). 
The 184 patients from whom this series of colorectal cancers were 
obtained were similar to the complete group of eligible colorectal 
cancer patients in the NLCS with respect to age at diagnosis, sex, 
TNM stage ( 19 ), and tumor location. This study was approved 
by the Medical Ethical Committee (MEC) of the Maastricht 
University Medical Center. 
 DNA Isolation 
 A 5- µ m section of each tissue block was stained with hematoxylin and 
eosin and reviewed by the study pathologist (A. P. de Bruïne). Five 
sections (20  µ m thick) were deparaffinized and subjected to genomic 
DNA extraction by using a Puregene DNA isolation kit (Qiagen, 
Hilden, Germany) according to the manufacturer ’ s instructions. 
 Collection and Preparation of Fecal DNA 
 Stool samples were obtained from healthy colonoscopy-negative 
control subjects older than 50 years who underwent colonoscopy 
screening for colorectal cancer within the framework of a work-
place-based community colorectal cancer study at the Maastricht 
University Medical Center. Stool samples and colorectal cancer 
tissues were collected from colonoscopy-confirmed colorectal can-
cer case patients who were diagnosed with all stages of colorectal 
cancer at the VU University Medical Center in Amsterdam. Two 
independent sets of noncancerous control subjects and colorectal 
cancer patients were included in this study: a training set consisting 
of 28 colorectal cancer patients and 45 noncancerous control sub-
jects and a test set consisting of 47 colorectal cancer patients and 
30 noncancerous control subjects. Series characteristics are shown 
in Supplementary Table 3 (available online). The MEC of the 
Maastricht University Medical Center and the Dutch Health 
Council approved this study. Written informed consent was 
obtained from all subjects who provided stool samples. All control 
stool samples from both sets of patients, one colorectal cancer 
stool sample from the training set, and three colorectal cancer 
stool samples from the test set were collected within 2 weeks 
before colonic purgation and colonoscopy. Twenty-seven colorec-
tal cancer stool samples from the training and 44 colorectal cancer 
stool samples from the test set were collected 5 – 7 days after 
colonoscopy and before resection of the tumor. 
 Stool stabilization buffer was added to the stool sample by the 
subject immediately after defecation (EXACT Sciences, 
Marlborough, MA), and stool samples were processed within 
48 hours after defecation. For recovery of human DNA, whole-stool 
samples were homogenized in a sevenfold excess volume of stool 
stabilization buffer and aliquoted in 32-mL portions that con-
tained the equivalent of 4 g of stool each. Single aliquots were 
centrifuged at 13 100 g for 2 minutes, and the supernatants were 
incubated with RNase A (80 U/mL) for 60 minutes at 37°C. Total 
DNA was precipitated by using 2.2 mL of 3 M sodium acetate 
(pH 5.2) and 22 mL of 100% isopropanol, centrifuged at 4500 g for 
5 minutes, and resuspended in 4 mL of 1 mM EDTA, 0.01 M 
Tris – HCl (pH 7.4). 
 Half of each DNA sample was stored at   20°C, and the other 
half was purifi ed as follows. Stool lysis buffer (1.5 mL; ASL buffer; 
Qiagen) and an InhibitEX tablet (Qiagen) were added to 2 mL of 
the DNA sample, and the mixture was centrifuged at 4500 g for 
5 minutes. After centrifugation, the supernatant was pipetted into 
a new tube and the pellet was discarded. We added 2 mL of the 
supernatant to 150  µ L of proteinase K (>600 mAU/mL; Qiagen), 
then added 2.4 mL of lysis buffer (AL buffer; Qiagen), and incu-
bated the mixture for 10 minutes at 70°C. We next added 2 mL of 
ethanol to the incubated sample, and the mixture was loaded onto 
a QiAamp Midi column (Qiagen), which was centrifuged at 1850 g 
for 3 minutes. The column was washed sequentially with 2 mL of 
wash buffer 1 (AW1 buffer; Qiagen) and 2 mL of wash buffer 2 
(AW2 buffer; Qiagen), with centrifugation at 4500 g for 15 minutes. 
We added 200  µ L of elution buffer (buffer AE; Qiagen) onto the 
membrane of the column, and the column was incubated at room 
temperature for 5 minutes. Finally, the column was centrifuged at 
4500 g for 2 minutes. The eluted fecal DNA (2  µ g) was subjected 
to bisulfi te modifi cation in 96-well plates (Tecan, Männedorf, 
Switzerland) by using an EZ-96 DNA Methylation kit (Zymo 
Research Co, Orange, CA) according to the manufacturer’s proto-
col. Bisulfi te-treated fecal DNA was concentrated by using a DNA 
Clean & Concentrator kit (Zymo Research Co).  NDRG4 promoter 
methylation in fecal DNA was analyzed by quantitative methylation-
specifi c PCR as described below. 
 Sodium Bisulfite Conversion, Sequencing, and 
Quantitative Methylation-Specific PCR 
 Sodium bisulfite modification, which converts unmethylated cyto-
sine residues to uracil residues, was carried out on 500 ng genomic 
DNA isolated from the tissue sections and colorectal cancer cell 
lines (HT29, SW48, CaCo2, Colo205, RKO, LS174T, HCT116, 
and SW480) with the use of an EZ DNA methylation kit (Zymo 
Research Co) according to the manufacturer’s instructions.  NDRG4 
methylation-specific PCR analysis was performed on bisulfite-
modified DNA as described in detail elsewhere ( 20 , 21 ). 
 For sequencing, bisulfi te-modifi ed DNA was amplifi ed using 
methylation-specifi c primers (shown in Supplementary Table 3, 
available online) and a PCR profi le consisting of an initial denatur-
ation at 95°C for 5 minutes; followed by 35 cycles of 30 seconds at 
95°C, 30 seconds at 60°C, and 1 minute at 72°C; and a fi nal exten-
sion at 72°C for 5 minutes. PCR products were cloned by using a 
TOPO-TA cloning kit (Invitrogen, Breda, the Netherlands), and six 
independent bacterial clones were sequenced by using an automated 
DNA sequencer (Applied Biosystems, Foster City, CA). Quantitative 
methylation-specifi c PCR was performed by using a 7900HT real-
time PCR system (Applied Biosystems) as follows: 2.4  µ L bisulfi te-
modifi ed DNA was added to a PCR mix containing buffer [16.6 mM 
(NH 4 ) 2 SO 4 , 67 mM Tris, 6.7 mM MgCl 2 , 10 mM   -mercaptoetha-
nol], dATP, dCTP, dGTP, and dTTP (each at 5 mM), forward 
primer (6 ng/ µ L), reverse primer (18 ng/ µ L), a single-stranded oli-
gonucleotide hybridization probe (0.16  µ M), bovine serum albumin 
(BSA; 0.1  µ g), and Jumpstart  Taq polymerase (0.4 U; Sigma –
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The PCR program was as follows: 5 minutes at 95°C; followed by 
45 cycles of 30 seconds at 95°C, 30 seconds at 57°C, and 30 seconds 
at 72°C; followed by 5 minutes at 72°C. Serially diluted plasmids 
(20 – 2 000 000 copies) containing the target sequence were amplifi ed 
to generate a standard curve against which the unknown samples are 
quantifi ed by interpolation of their PCR cycle number (Ct value) to 
the corresponding plasmid copy. Primer sequences are provided in 
Supplementary Table 3 (available online). Samples were handled 
and analyzed in a blinded fashion during storage, DNA isolation, 
and PCR analysis.  One quantitative methylation-specifi c PCR 
experiment was performed for each independent  set of patients . 
 Cell Culture and Transfections 
 Human colorectal cancer cell lines (HT29, SW48, CaCo2, 
Colo205, RKO, LS174T, HCT116, and SW480; all from LGC, 
Teddington, UK) were cultured in Dulbecco’s modified Eagle 
medium (DMEM) (Invitrogen) supplemented with 10% heat-
inactivated fetal calf serum (FCS; HyClone, Etten-Leur, the 
Netherlands). To investigate the effect of reexpression of  NDRG4 , 
RKO and HCT116 cells were treated for 3 days with 1  µ M DAC 
(Sigma). The full-length  NDRG4 cDNA (Origene, Rockville, MD) 
was subcloned into a pCMV6-Neo vector (Origene) to create 
pCMV6-NDRG4. HCT116 cells were transfected with pCMV6-
NDRG4 or empty vector (pCMV6) by use of a Nucleofector Kit 
V (Amaxa Biosystems, Gaithersburg, MD) according to the manu-
facturer’s guidelines. RKO cells were transfected with pCMV6-
NDRG4 or pCMV6 by using Lipofectamine 2000 Reagent 
(Invitrogen) according to the manufacturer’s protocol. Transfected 
HCT116 and RKO cells were grown for 10 days in medium con-
taining G418 (at 400  µ g/mL for HCT116 and 1 mg/mL for RKO; 
Invitrogen) to select for cells that were stably transfected with the 
pCMV6-based plasmids. 
 Quantitative Real-Time PCR 
 Total RNA was isolated from colorectal cancer cell lines and tis-
sues from patients and control subjects by using an RNeasy Mini 
kit (Qiagen) according to the manufacturer’s instructions and 
treated with RNase-free DNAse (Qiagen) to remove contaminat-
ing genomic DNA. cDNA was synthesized from 1  µ g of the 
DNAse-treated RNA by using an Iscript cDNA synthesis kit 
(Bio-Rad, Hercules, CA). Quantitative real-time PCR to quantify 
NDRG4 mRNA levels was performed by using SYBR Green PCR 
master mix (Applied Biosystems, Nieuwekerk a/d IJssel, the 
Netherlands) as described previously ( 22 ). Cyclophilin A was used 
as a reference gene for normalization. Primers used are listed in 
Supplementary Table 3 (available online). 
 Immunohistochemistry 
 Immunohistochemistry was performed on formalin-fixed, paraf-
fin-embedded tissue sections (5  µ m thick). Sections were deparaf-
finized in xylene, rehydrated, and incubated with 0.3% hydrogen 
peroxide in methanol for 30 minutes. The sections were incu-
bated with Tris-buffered saline (TBS), 20% FCS, and 0.1% 
Tween to block nonspecific antibody binding, followed by incu-
bation with the anti-NDRG4 monoclonal antibody (Abnova 
Corporation, Taipei City, Taiwan) diluted 1:6000 in TBS with 
0.1% Tween and 0.5% BSA. Sections were incubated with a 
horseradish peroxidase – conjugated secondary antibody against 
mouse, rabbit, and rat IgGs (Poly-HRP GAM/R/R IgG) 
(Immunovision Technologies, Burlingame, CA), and bound anti-
body was visualized by using 3,3-diaminobenzidine substrate as a 
chromogen (Dako, Glostrup, Denmark) followed by hematoxylin 
counterstaining. 
 Colony Formation Assay 
 Colorectal cancer RKO and HCT116 cells were transfected in six-
well plates (1 × 10 6 cells per well) with pCMV6 or pCMV6-
NDRG4 as described above. The next day, the cells were diluted 
1:20 and G418 (at 1 mg/mL for RKO 400  µ g/mL for HCT116) 
was added to the medium to select for cells in which the plasmids 
had stably integrated into genomic DNA. After 14 days of selec-
tion, colonies were stained by using Giemsa’s azur eosin methylene 
blue solution (Merck, Darmstadt, Germany) and counted. Colony 
formation was assessed in four different experiments (two replicate 
wells per experiment). 
 In Vitro Cell Proliferation, Migration, and Invasion Assays 
 HCT116 cells were seeded onto 96-well plates (5000 cells per 
well), and cell numbers were counted 24, 48, 72, and 96 hours later 
(three wells per time point). In addition, after 96 hours of incuba-
tion, the cultures were pulse labeled for 6 hours with [methyl- 3 H]
thymidine (0.3  µ Ci per well; Amersham Life Science, Roosendaal, 
the Netherlands). Cells were harvested by using a cell harvester, 
and [ 3 H]thymidine activity was measured by using a liquid scintil-
lation counter. Three independent experiments were performed 
(three replicate wells per experiment). 
 Cell migration and invasion assays were performed using 
matrigel-coated (invasion assay) or uncoated (migration assay) 
24-well transwell plates (8- µ m pore size) (BD Biosciences, Franklin 
Lakes, NJ). Briefl y, 2 × 10 5 HCT116 cells in DMEM containing 
1% FCS were seeded into the upper chamber of each well, and 
DMEM containing 20% FCS was placed in the lower chamber. 
After 48 hours of incubation, the transwells were disassembled and 
the membranes that separated the upper and lower chamber of 
each transwell were fi xed with methanol and stained with 1% 
toluidine blue in 1% borax and the cells on the lower surface of the 
membrane were counted with the use of a light microscope. 
Transwell experiments were assessed in three different experi-
ments (two replicate wells per experiment). 
 Statistical Analysis 
 For comparison between  NDRG4 methylation frequencies in 
normal, adenoma, and carcinoma tissues from colorectal cancer 
patients and normal and adenoma tissues from control subjects 
without colorectal cancer, we used logistic regression ( Table 1 ). 
Because we observed statistically significant differences in age 
between the cancer patients and control subjects (analyzed using 
one-way analysis of variance [ANOVA]) and in tumor location 
among the cancer patients (analyzed using Pearson   2 test) 
(Supplementary Table 1, available online), logistic regression 
analyses were adjusted for age and location. To compare the 
prevalence of  NDRG4 promoter methylation in colorectal cancer 
tissue in relation to clinicopathological features, the Pearson   2 
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(age at diagnoses) was used ( Table 2 ). In the hospital-based 
series, noncancerous control tissues, adenoma tissues, and carci-
noma tissues were obtained from the same patients. These paired 
samples were analyzed by using the McNemar test to compare 
 NDRG4 methylation frequencies in carcinoma, adenoma, and 
normal tissues from colorectal cancer patients ( Table 3 ). Where 
appropriate, the Bonferroni method was used to correct for mul-
tiple comparisons. 
 For quantitative methylation-specifi c PCR analysis, we used 
receiver operating characteristic (ROC) curve analysis and the 
area under the curve (AUC) to determine the best cutoff value for 
highest sensitivity and specifi city.  NDRG4 promoter methylation 
was considered positive if the methylation value was greater than 
the cutoff. Because age differences were expected between cancer 
patients and control subjects, an ROC curve and generalized 
linear (ROC-GLM) regression model was used to assess the 
infl uence of the age difference on the accuracy of  NDRG4 methy-
lation as a biomarker for the detection of colorectal cancer. 
 Analysis of cell growth curves was performed by means of 
two-way ANOVA. The Student  t test was used for analyses of 
[ 3 H]thymidine incorporation and anchorage-independent cell 
growth. The Mann – Whitney rank sum test was used to analyze 
data obtained in the colony formation, quantitative real-time 
PCR, migration, and invasion assays. 
 All  P values are two-sided, and  P values less than or equal to .05 
were considered statistically signifi cant. Data analysis was done by 
using SPSS software (version 12.0.1; SPSS Inc., Chicago, IL) 
 Results 
 NDRG4 Promoter Methylation and mRNA Expression in 
Colorectal Cancer Cell Lines 
 The promoter region of the  NDRG4 gene (National Center for 
Biotechnology Information [NCBI] accession number  NM _020465) 
contains a dense CpG island located from nucleotides   556 to 
+869 relative to the transcription start site ( Figure 1, A ). To assay 
this region for potential methylation, we examined eight human 
colorectal cancer cell lines by methylation-specific PCR using 
primers located from   250 to +10 relative to the transcription 
start site (primers are listed in Supplementary Table 3, available 
online). The  NDRG4 promoter was methylated in all of the cell 
lines except SW480 ( Figure 1, B ). To investigate the pattern of 
CpG island methylation in the  NDRG4 promoter, we sequenced 
sodium bisulfite – modified genomic DNA isolated from HCT116 
( NDRG4 promoter methylation positive) and SW480 ( NDRG4 
promoter methylation negative) cells. The promoter region 
spanning 39 CpG sites (  251 to +10) was PCR amplified using 
sodium bisulfite – modified genomic DNA as template. Bisulfite 
sequencing confirmed the methylation-specific PCR data in that 
HCT116 cells showed almost complete methylation, whereas 
SW480 cells showed almost no methylated CpGs ( Figure 1, C ). 
To investigate whether promoter methylation was associated 
with inhibition of gene expression, we measured  NDRG4 mRNA 
levels in HCT116 and RKO cells incubated with and without the 
DNA methylation inhibitor DAC. In both cell lines, endogenous 
 NDRG4 mRNA levels were statistically significantly higher in 
DAC-treated cells than in untreated cells (DAC treated vs 
untreated, RKO cells: 4.4-fold increase, 95% confidence interval 
[CI] = 3.17- to 5.63-fold increase,  P = .014; HCT116 cells: 1.7-
fold increase, 95% CI = 0.93- to 2.47-fold increase,  P = .037) 
( Figure 1, D ). 
 Table 1 .  NDRG4 promoter methylation frequencies in normal, adenoma, and carcinoma tissues from CRC patients and normal and 











 P  CRC patients Control subjects CRC patients Control subjects 
 NDRG4 p1 71/83 (86) 2/48 (4) <.001 9/78 (12) 2/48 (4) >.99 41/62 (66%) 12/22 (55) >.99 
 NDRG4 p2 55/77 (71) 0/28 (0) <.001 2/80 (3) 0/28 (0) >.99 24/58 (41%) 4/31 (13) >.99 
 *  Methylation frequency is presented as the number of methylated samples divided by the total number of samples analyzed (%).  P values (two-sided) were generated 
by using logistic regression with adjustment for age (continuous data) and tumor location (categories: proximal and distal location).  P values are Bonferroni adjusted, 
and the cutoff for statistical significance is  P = .017. CRC = colorectal cancer; NDRG4 = N-Myc downstream-regulated gene 4; MSP = methylation-specific poly-
merase chain reaction; p1 = methylation-specific primer pair 1; p2 = methylation-specific primer pair 2. 
 Table 2 .  Prevalence of  NDRG4 promoter methylation in colorectal 
cancer tissue in relation to clinicopathological features for two 






 TNM stage §   
  I 11/12 (92) 30/42 (71) 
  II 23/28 (82) 42/57 (74) 
  III 29/32 (91) 39/56 (70) 
  IV 8/11 (72) 17/21 (81) 
   P .431 .790 
 Tumor location   
  Proximal 34/39 (87) 47/58 (81) 
  Distal 37/42 (89) 81/118 (69) 
   P 1.00 .141 
 Sex   
  Male 34/41 (83) 71/95 (75) 
  Female 37/42 (88) 57/81 (70) 
   P .548 .611 
 Age at diagnosis, y   
  ≤ 70 30/32 (94) 83/117 (71) 
  >70 41/51 (80) 45/59 (76) 
   P .117 .453 
 *  Methylation frequency is presented as the number of methylated samples 
divided by the total number of samples analyzed (%).  P values are from two-
sided   2 tests. NDRG4 = N-Myc downstream-regulated gene 4. 
 †  Collected from the tissue archive of the Department of Pathology of the 
University Hospital Maastricht. 
 ‡  Prospective Netherlands Cohort Study on Diet and Cancer. 
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 Prevalence of  NDRG4 Promoter Methylation in Primary 
Colorectal Adenomas and Carcinomas 
 Sequence analysis of sodium bisulfite – modified genomic DNA 
isolated from three pairs of primary colorectal cancer tissues and 
matched noncancerous colon normal mucosa showed dense meth-
ylation at the  NDRG4 promoter (region   251 to +10 relative to 
the transcription start site) in the colorectal cancers but almost no 
 NDRG4 promoter methylation in matched normal colon mucosa 
( Figure 2, A ). It is interesting that the density of methylation was 
higher in the upstream region (ie, the region more 5 ′ relative to the 
transcription start site) of the  NDRG4 CpG island than in the 
more downstream region ( Figure 2, A ). 
 To examine the methylation status of the  NDRG4 promoter in 
a large series of noncancerous colon mucosa, adenoma, and col-
orectal cancer tissues, we performed methylation-specifi c PCR 
with primer pair 1 (which is situated more to the 5 ′ -end of the 
 NDRG4 promoter region, where the  NDRG4 methylation density 
was higher compared with the upstream region;  Figure 1, A ). The 
frequency of  NDRG4 promoter methylation was lower in the nor-
mal mucosa from the control subjects than in the colorectal cancer 
 Table 3 .  NDRG4 promoter methylation frequencies in carcinoma, adenoma, and normal tissues from colorectal cancer patients * 
 MSP primer Normal tissue Adenoma tissue  P Normal tissue Carcinoma tissue  P Adenoma tissue Carcinoma tissue  P 
 NDRG4 p1 5/36 (14) 22/36 (61) <.001 5/31 (16) 26/31 (84) <.001 20/32 (63) 26/32 (81) .540 
 NDRG4 p2 0/32 (0) 11/32 (34) .003 0/30 (0) 22/30 (73) <.001 13/33 (39) 25/33 (76) .012 
 *  Methylation frequency is presented as the number of methylated samples divided by the total number of samples analyzed (%). Frequencies for some types of 
tissue vary because for some patients we did not have simultaneous information on both types of tissue in the analysis (eg, not all patients with adenomas 
also had both normal and carcinoma tissue available).  P values (Bonferroni adjusted) are from a two-sided McNemar test; the cutoff for statistical significance is 
 P = .017. NDRG4 = N-Myc downstream-regulated gene 4; MSP = methylation-specific polymerase chain reaction. 
 Figure 1 .  N-Myc downstream-regulated gene 4 ( NDRG4 ) promoter 
structure, promoter methylation, and mRNA expression in colorectal 
cancer cell lines.  A ) Schematic representation of the promoter region of 
 NDRG4 (NM_020465). A dense CpG island is located between nucle-
otides   556 and +869 relative to the transcription start site (TSS). 
 Vertical lines represent the locations of CpG dinucleotides, the  gray 
rectangle indicates the open reading frame (ORF) of  NDRG4 , and  paired 
arrows indicate the locations of the amplicons identifi ed by methyla-
tion-specifi c polymerase chain reaction (MSP), quantitative MSP 
(qMSP), and bisulfi te sequencing (BS) primers.  B ) Electrophoretic 
analysis of MSP amplifi cation products in eight colorectal cancer cell 
lines. U = unmethylated, M = methylated, IVD = in vitro methylated 
DNA, NL = normal lymphocytes.  C ) Bisulfi te sequencing of colorectal 
cancer HCT116 and SW480s. Six different bacterial clones were 
sequenced. Each  row represents an individual cloned allele that was 
sequenced following sodium bisulfi te DNA modifi cation. Each  box 
indicates a CpG dinucleotide ( black box = methylated CpG site;  white 
box = unmethylated CpG site).  D ) NDRG4 mRNA expression in colorec-
tal cancer RKO and HCT116 cells with and without treatment with the 
DNA methylation inhibitor 5-aza-2 ′ -doxycytidine (DAC). Quantifi cation 
is presented as mean values ( error bars correspond to 95% confi dence 
intervals) relative to untreated cells from three independent experi-
ments (normalization was against cyclophilin A). Statistical analysis 
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tissue from the colorectal cancer patients (2/48 [4%] vs 71/83 
[86%];  P < .001) ( Table 1 ). The frequency of  NDRG4 promoter 
methylation in adjacent normal mucosa of colorectal cancer 
patients did not differ statistically signifi cantly from that in the 
normal mucosa of control subjects (9/78 [12%] vs 2/48 [4%]; 
 P > .99) ( Table 1 ). Little or no  NDRG4 promoter methylation 
was found in skin, renal cell, ovarian, prostate, breast, or esopha-
geal squamous cell carcinomas (data not shown). By contrast, the 
 NDRG4 promoter was frequently methylated in adenocarcinomas 
of the esophagus (13/16 [81%]) and in diffuse-type (8/11 [73%]) 
and intestinal-type (9/11 [82%]) adenocarcinomas of the stomach 
(data not shown). We also compared the frequency of  NDRG4 
promoter methylation in premalignant lesions from patients with 
and without colorectal cancer. We observed no statistically signifi -
cant difference in the frequency of  NDRG4 promoter methylation 
between adenomas obtained from colorectal cancer patients that 
developed synchronously or metachronously to the tumor and 
adenomas obtained from patients that did not develop colorectal 
cancer after 10 years of follow-up (41/62 [66%] vs 12/22 [55%]; 
 P > .99) ( Table 1 ). 
 To confi rm the high prevalence of  NDRG4 promoter methylation 
in colorectal cancer, we analyzed a second independent, population-
based series of colorectal cancers and observed that  NDRG4 pro-
moter methylation was present in 70% (128/184) of colorectal 
cancer patients (data not shown). In each of the two independent 
series of colorectal cancer patients,  NDRG4 promoter methylation 
was not associated with age at diagnosis (mean age = 70 years), sex, 
proximal vs distal tumor location, or TNM stage ( Table 2 ). 
 We next investigated whether  NDRG4 promoter methylation 
changes during colorectal cancer progression by comparing the 
frequency of  NDRG4 promoter methylation in samples of normal 
mucosa, adenoma, and colorectal cancer tissues ( Table 3 ). The 
 NDRG4 promoter was more frequently methylated in colorectal 
carcinomas than in matched normal mucosa adjacent to the tumor 
(26/31 [84%] vs 5/31 [16%];  P < .001) ( Table 3 ). Adenoma samples 
from colorectal cancer patients also had a statistically signifi cantly 
higher  NDRG4 promoter methylation frequency than normal 
colon samples (22/36 [61%] vs 5/36 [14%];  P < .001) ( Table 3 ). 
Finally, the frequency of  NDRG4 promoter methylation was 
higher in colorectal carcinomas than in matched adenoma samples, 
but the difference was not statistically signifi cant (26/32 [81%] vs 
20/32 [63%];  P = .54) ( Table 3 ). 
 Heterogeneity of  NDRG4 Promoter Methylation 
 As described above, we observed that the density of methylation 
was higher in the upstream region of the  NDRG4 promoter CpG 
island than in the more downstream region. We therefore used 
methylation-specific PCR primer pair 2, which amplifies a region 
downstream of primer pair 1 ( Figure 1, A ), to investigate this 
region for  NDRG4 promoter methylation. The sensitivity for col-
orectal cancers (the proportion of people with disease who have a 
positive test result) decreased from 86% with primer pair 1 to 71% 
with primer pair 2, whereas the specificity (the proportion of 
people without disease with a negative test result) increased from 
96% to 100%. Intriguingly, using primer pair 2, we found a statis-
tically significant difference in the frequency of  NDRG4 promoter 
 Figure 2 .  N-Myc downstream-regulated gene 4 ( NDRG4 ) promoter 
methylation and expression in primary colorectal cancer.  A ) Bisulfi te 
sequencing of colorectal cancer (T1 – 3) and the matched normal 
colon mucosa (N1 – 3) from three colorectal cancer patients. Six dif-
ferent bacterial clones per tissue sample were sequenced. Each  row 
represents an individual cloned allele that was sequenced following 
sodium bisulfi te DNA modifi cation. Each  box indicates a CpG dinu-
cleotide ( black box = methylated CpG site;  white box = unmethylated 
CpG site).  B ) NDRG4 mRNA levels measured by real-time poly-
merase chain reaction in colon cancer tissues (T) and matched nor-
mal colon tissue samples (N) from the three colorectal cancer 
patients in (A). For each patient, the level of NDRG4 mRNA expres-
sion in normal mucosa tissue was set to equal 1. Data are presented 
as mean values relative to normal mucosa tissue of three indepen-
dent experiments ( error bars correspond to 95% confi dence inter-
vals). Statistical analysis was performed using the Mann – Whitney 
rank sum test (two-sided).  C ) Immunohistochemical localization of 
NDRG4 protein expression in normal colon mucosa (a, ×10 magnifi -
cation) and colorectal cancer (b, c, ×40 magnifi cation).  Blue (hema-
toxylin) staining represents the nuclear staining and  brown (DAB) 
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methylation between matched adenomas and carcinomas from the 
colorectal cancer patients (13/33 [39%] vs 25/33 [76%];  P = .012), 
which was not observed using primer pair 1 ( Table 3 ). 
 NDRG4 mRNA and Protein Expression in Colorectal 
Cancer 
 We next examined whether methylation of the CpG island in the 
 NDRG4 promoter is associated with gene silencing by investigat-
ing NDRG4 mRNA expression in colorectal cancer tissue and 
matched normal colon mucosa from three colorectal cancer 
patients. In each of the three pairs of tissue, the NDRG4 mRNA 
level in the colorectal cancer was statistically significantly lower 
than that in the matched normal colon mucosa ( P = .037 for all 
three matched pairs). Compared with the NDRG4 mRNA level in 
the matched normal tissue (set at 100%), the expression of  NDRG4 
in tumor 1, 2, and 3 was 3% (95% CI =   3% to 8%), 31% (95% 
CI = 9% to 58%), and 1.5% (95% CI = 1.3% to 1.7%), respec-
tively ( Figure 2, B ). 
 Next, we performed immunohistochemistry to investigate 
NDRG4 protein expression in a matched pair of normal colonic 
mucosa and colorectal cancer tissue from a colorectal cancer 
patient. In normal colon mucosa, NDRG4 expression was pre-
dominantly in basolateral membranes within colonocytes and 
increased in intensity near the mucosal surface ( Figure 2, C , panel 
a). The matched colorectal cancer tissue showed heterogeneous 
cytoplasmatic staining with the anti-NDRG4 antibody. Similar 
results were observed in matched pairs of tissues from other col-
orectal cancer patients (data not shown). In most tumors, less than 
50% of the tumor area showed weak to focally strong NDRG4 
expression ( Figure 2, C , panels b and c). 
 To investigate the association between  NDRG4 promoter 
methylation and NDRG4 expression, we performed immunohis-
tochemical analysis of NDRG4 protein expression on tissues from 
80 colorectal cancer patients of the population-based series. We 
observed no association between  NDRG4 promoter methylation 
and NDRG4 expression, suggesting that an alternative mechanism 
might account for  NDRG4 inactivation in colorectal cancer. 
Therefore, we analyzed macrodissected colorectal cancer tissue and 
matched normal tissues from 86 colorectal cancer case patients of 
the population-based series for loss of heterozygosity. In addition, 
12 primary colorectal cancers and the colorectal cancer cell lines 
HCT116 and SW480 were analyzed for  NDRG4 mutations. We 
observed loss of heterozygosity in 27 (31%) of 86 colorectal cancers. 
No inactivating mutations within the coding region of the  NDRG4 
gene were detected in the 12 colorectal carcinomas. However, we 
found one novel nonsynonymous mutation in the SW480 cell line 
(40662A → AG Ile65Val [an A-to-G substitution at nucleotide 4066, 
resulting in an isoleucine-to-valine substitution at amino acid 65]). 
In addition, two previously reported single-nucleotide polymor-
phisms (SNPs) were detected among the 12 colorectal cancers. 
One SNP was observed in one of the 12 colorectal cancers 
(43760G → GG Val224Val [a G-to-GG substitution at nucleotide 
43760, no difference in amino acid]); NCBI SNP database 
[dbSNP] accession number rs17821543). The second SNP was 
observed in nine of the 12 colorectal cancers (48311A → AG 
Ser354Ser [an A-to-AG substitution at nucleotide 43760, no dif-
ference in amino acid]; NCBI dbSNP accession number rs42945). 
 Effect of NDRG4 Overexpression in Colorectal Cancer Cell 
Lines 
 To examine whether NDRG4 acts as a tumor suppressor in 
colorectal cancer cells, we characterized HCT116 and RKO 
cells that were transfected with an expression vector harboring 
the full-length NDRG4 cDNA or empty vector (control). 
NDRG4 transfectants (pools of stably transfected cells) showed 
increased expression of NDRG4 mRNA compared with control 
cells transfected with empty vector (HCT116 52%,  P = .005; 
RKO 69%,  P = .037). In addition, NDRG4 protein expression 
was increased in the NDRG4 transfectants compared with the 
control cells transfected with empty vector (data not shown). 
Compared with control transfectants, transfection with NDRG4 
statistically significantly reduced the number of G418-resistant 
colonies (HCT116: 77% reduction [95% CI = 66% to 90% 
reduction],  P = .014; RKO: 69% reduction [95% CI = 61% to 
76% reduction],  P = .014) ( Figure 3, C and D ) and statistically 
significantly decreased cell proliferation as measured by [ 3 H]
thymidine activity (HCT116: 40% reduction [95% CI = 27% to 
44% reduction],  P < .001) ( Figure 3, E and F ). NDRG4 trans-
fectants displayed reduced invasion through matrigel-coated 
transwell membranes compared with control transfectants 
(HCT116: 48% reduction [95% CI = 31% to 64% reduction],
  P < .001) ( Figure 3, G ). However, transfection of NDRG4 had 
no effect on HCT116 cell migration compared with control-
transfected cells ( Figure 3, H ). Taken together, these data sug-
gest that NDRG4 exhibits tumor-suppressive effects in human 
colorectal cancer cells. 
 Sensitivity and Specificity of NDRG4 Promoter 
Methylation in Fecal DNA for the Detection of Colorectal 
Cancer 
 The high prevalence of  NDRG4 promoter methylation in col-
orectal cancer and the absence of methylation in normal colon 
mucosa suggested that  NDRG4 promoter methylation could be 
a sensitive and specific biomarker for the noninvasive detection 
of colorectal cancer in human stool. Therefore, we developed a 
quantitative molecular beacon – based methylation-specific PCR 
assay that used a primer pair situated between methylation-
specific PCR primer pair 1 and methylation-specific PCR 
primer pair 2 and fecal DNA isolated from stool ( Figure 1, A ). 
We first examined  NDRG4 promoter methylation as a bio-
marker for colorectal cancer in a training set comprising 28 
colorectal cancer patients and 45 healthy control subjects. We 
used the data from the training set to construct an ROC curve 
with an AUC of 0.77 (95% CI = 0.66 to 0.86) ( Figure 4 ). Using 
a cutoff level of 1.22 copies, which gave the highest sensitivity 
and specificity for the detection of colorectal cancer, we detected 
 NDRG4 promoter methylation in 17 of the 28 colorectal cancer 
patients, yielding a sensitivity of 61% (95% CI = 43% to 79%) 
for the detection of colorectal cancer. Three (7%) of the 45 
healthy control subjects tested positive for  NDRG4 methylation, 
which resulted in a specificity of the assay of 93% (95% CI = 90% 
to 97%). To test the accuracy of the  NDRG4 promoter methylation 
cutoff generated from the training set, we assayed  NDRG4 pro-
moter methylation by using quantitative methylation-specific 
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and 30 healthy control subjects, which were handled in a blinded 
fashion. Using the previously determined cutoff level of 1.22 
methylated copies, we found that 25 of the 47 colorectal cancer 
patients tested positive for  NDRG4 methylation, resulting in a 
sensitivity of 53% (95% CI = 39% to 67%), and that none of the 
30 control subjects tested positive, yielding a specificity of 100% 
(95% CI = 86% to 100%). 
 Because the mean age of the colorectal cancer patients dif-
fered statistically signifi cantly from that of the control subjects in 
the training and test set (Supplementary Table 4, available 
online), we used an ROC-GLM regression model in the training 
set to assess the accuracy of  NDRG4 promoter methylation for 
the detection of colorectal cancer after adjustment for age. This 
analysis indicated that age did not statistically signifi cantly infl u-
ence the accuracy ( P = .89, ROC-GLM regression model) ( 23 ). 
These data indicate that detection of  NDRG4 promoter methyla-
tion in fecal DNA can be used as a novel biomarker for detection 
of colorectal cancer. 
 Discussion 
 Here we describe the identification and validation of  NDRG4 pro-
moter methylation, a novel, sensitive, and specific marker for the 
detection of colorectal cancer. We found a statistically significant 
difference in the frequency of  NDRG4 promoter methylation 
between colorectal cancer and normal colon mucosa. Adding 
inflamed mucosa, which often shows promoter CpG island methy-
lation ( 24 ), to the normal colon mucosa control group only slightly 
reduced the specificity of  NDRG4 promoter methylation from 96% 
to 94%, indicating that  NDRG4 promoter methylation is not asso-
ciated with inflammation. Although most CpG island promoter-
methylated genes are frequently associated with a proximal tumor 
location ( 25 ),  NDRG4 promoter methylation is present in both 
distal colorectal cancers [often associated with chromosomal insta-
bility ( 26 )] and proximal colorectal cancers (often associated with 
microsatellite instability). This finding makes  NDRG4 promoter 
methylation a promising marker to detect chromosomal-instable as 
 Figure 3 .  Functional assays of N-Myc downstream-regulated gene 4 
(NDRG4) in colorectal cancer. ( A ,  B ) NDRG4 mRNA expression mea-
sured by real-time polymerase chain reaction in HCT116 (A) and RKO 
(B) cells stably transfected with NDRG4 expression vector (pCMV6-
NDRG4) or empty vector (pCMV6). Results are plotted as mean values 
of mRNA expression relative to control vector in fi ve (HCT116) and 
three (RKO) independent experiments (HCT116; * P = .005, RKO; * P = 
.037). ( C ,  D ) Colony formation by HCT116 (C) and RKO (D) cells trans-
fected with pCMV6 or pCMV6-NDRG4 and grown for 2 weeks in 
medium containing G418. Results are plotted as the mean colony num-
bers relative to pCMV6 transfectants in four independent experiments 
(C and D: * P = .014). Statistical analysis in  panels A – D was performed 
using the Mann – Whitney rank sum test (two-sided).  E ) Cell proliferation 
assay. NDRG4-transfected HCT116 cells (pCMV6-NDRG4) were com-
pared with control cells transfected with empty vector (pCMV6). Results 
are plotted as the mean cell number in three independent experiments 
(72 hours: * P = .05; 96 hours: ** P < .001; two-way analysis of variance). 
 F ) Cell proliferation measured by  3 H-thymidine incorporation. Data are 
expressed as mean number of proliferating  NDRG4 -transfected cells 
relative to control cells transfected with empty vector (pCMV6). Three 
independent experiments were performed (three replicate wells per 
experiment) (* P < .001; two-sided Student  t test).  G ) Invasion of HCT116 
cells through matrigel-coated transwells. Results represent mean num-
ber of NDRG4-transfected cells that passed through the matrigel-coated 
membranes of the transwell relative to control cells transfected with 
empty vector in three independent experiments (* P < .001, two-sided 
Mann – Whitney rank sum test).  H ) Migration assay. Plotted are the mean 
number of NDRG4-transfected HCT116 cells that migrated through 
transwell membranes not coated with matrigel relative to control cells 
transfected with empty vector in three independent experiments (NS = 
not statistically signifi cantly different from control, Mann – Whitney rank 
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well as microsatellite-instable colorectal cancers. We also found 
that DNA methylation density was higher in the upstream region 
of the  NDRG4 promoter than in the downstream region. Therefore, 
we used two different pairs of methylation-specific PCR primers 
that amplify overlapping fragments in the CpG island to detect 
 NDRG4 promoter methylation. Using primer pair 1 (the one most 
5 ′ to the transcription start site) to detect  NDRG4 promoter methy-
lation resulted in a sensitivity for colorectal cancer of 86% and for 
adenoma of 66% and a specificity of 96%. Using primer pair 2, the 
sensitivity for colorectal cancers and adenomas decreased to 71% 
and 41%, respectively, whereas the specificity increased to 100%. 
This finding suggests that  NDRG4 promoter hypermethylation 
initially occurs at the 5 ′ -end of the  NDRG4 CpG island and spreads 
toward the transcription start site before ultimately shutting 
down  NDRG4 mRNA expression, as has also been observed in 
the promoter for  RUNX3 ( 27 , 28 ). 
 In addition, we found a statistically signifi cantly lower methyla-
tion frequency in adenoma tissue compared with carcinoma tissue 
when we used primer pair 2 to detect  NDRG4 promoter methyla-
tion. This fi nding suggests that DNA methylation in the promoter 
of  NDRG4 may spread toward the transcription start site during 
cancer progression. 
 To our knowledge, expression of  NDRG4 has been documented 
only in brain and heart tissue by Northern blotting. Here we show 
that NDRG4 mRNA and protein is expressed in normal colon tis-
sue and that expression of both is decreased in colorectal cancer. 
However, we found no statistically signifi cant association between 
 NDRG4 promoter methylation and NDRG4 expression. We and 
others ( 29 ) also found no evidence for mutational inactivation of 
 NDRG4. However, we observed loss of heterozygosity of the 
 NDRG4 locus at chromosome 16q in 31% of the colorectal cancers 
analyzed. Frequent loss of heterozygosity at 16q was previously 
observed in a wide variety of solid tumor types, including breast 
( 30 ), liver ( 31 , 32 ), prostate ( 33 ), ovarian ( 34 ), and Wilms tumors 
( 35 ), but, to our knowledge, has not been described in colorectal 
cancer. These fi ndings suggest that promoter methylation and loss 
of heterozygosity contribute to the altered expression of  NDRG4 
in colorectal cancer. 
 We also provide evidence that NDRG4 has tumor suppres-
sor activities in colorectal cancer. Overexpression of  NDRG4 in 
the colorectal cancer HCT116 cells inhibited colony formation 
and cell proliferation and invasion in vitro, suggesting that 
 NDRG4 is a tumor suppressor gene in colorectal cancer. The 
ability of the  NDRG4 -transfected cells to migrate in vitro was 
identical to that of control cells, which was also observed for 
 NDRG1 ( 4 ). 
 To investigate the potential utility of  NDRG4 promoter methy-
lation as a noninvasive biomarker test to identify individuals who 
should undergo colonoscopy because they are at increased risk for 
colorectal cancer, we analyzed fecal DNA of colorectal cancer 
patients and control subjects. We showed that detection of 
 NDRG4 promoter methylation in fecal DNA was both sensitive 
and specifi c at identifying colorectal cancer patients in two inde-
pendent series of case patients and control subjects. The preva-
lence of  NDRG4 promoter methylation in colorectal cancer tissue 
(86% and 70% in two independent series) suggests that the use of 
optimal protocols for the isolation of fecal DNA could, in theory, 
yield a stool  NDRG4 quantitative methylation-specifi c PCR test 
with an even higher sensitivity. Methyl-binding domain protein 
columns to capture methylated DNA, which have been shown to 
markedly increase sensitivity without decreasing specifi city ( 36 ), 
may be useful in this respect. Several studies have provided proof 
of principle for the detection of promoter CpG island hyperm-
ethylation of colorectal adenoma or colorectal cancer – derived 
DNA in stool ( 37 – 43 ) and blood ( 44 – 49 ). Compared with other 
gene promoter methylation markers described thus far ( 37 – 39 ,
 44 – 48 ),  NDRG4 promoter methylation performs well as a novel 
single marker. Combining  NDRG4 promoter methylation with 
other DNA markers could improve its sensitivity and specifi city 
for the detection of colorectal cancer, as has been observed for 
other methylation markers ( 50 , 51 ). In addition, the specifi city of 
 NDRG4 promoter methylation for gastrointestinal adenocarcinomas 
makes it a specifi c biomarker for detecting gastrointestinal cancers 
in stool and blood. 
 The stool study presented here should be considered a pilot 
study that has specifi c limitations. Not all stool samples from col-
orectal cancer patients were collected before colonoscopy as was 
done for the control subjects. It is therefore possible, albeit very 
unlikely, that colonoscopy could have introduced artifacts in the 
observed methylation prevalence. In addition, the age of the col-
orectal cancer patients and control subjects differed statistically 
signifi cantly, which raises the question of whether the detected 
 NDRG4 promoter methylation is associated with age. However, 
this possibility is highly unlikely because neither data from the two 
independent colorectal cancer series nor the ROC-GLM regres-
sion analysis of the stool samples showed that  NDRG4 promoter 
methylation was associated with age. Nevertheless, the stool data 
  
 Figure 4 .  N-Myc downstream-regulated gene 4 ( NDRG4 ) promoter 
methylation in fecal DNA as biomarker for colorectal cancer detection. 
Sensitivity and specifi city at various cutoff values for the training set 
(which consisted of 28 colorectal cancer patients and 45 healthy control 
subjects) to obtain a positive test for  NDRG4 quantitative methylation-
specifi c PCR are shown in the receiver operating characteristic (ROC) 
curve. The  jagged line represents the ROC curve. The  dashed line rep-
resents the line of no discrimination between good and bad classifi ca-
tion. The determined optimal cutoff value for  NDRG4 promoter 
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should be validated in a large prospective screening study for col-
orectal cancer, as should  NDRG4 promoter methylation be com-
bined with other methylation markers to enhance the sensitivity 
and/or specifi city. 
 In conclusion, to our knowledge, this is the fi rst study to 
describe a tumor suppressor role for  NDRG4 in cancer. Our data 
indicate that  NDRG4 promoter methylation is potentially useful as 
a sensitive and specifi c noninvasive preselection modality for iden-
tifying individuals at risk for colorectal cancer for whom colonos-
copy is recommended. 
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